术中氯胺酮预防外周神经阻滞后严重反跳痛:前瞻性随机双盲安慰剂对照研究
该前瞻性随机双盲安慰剂对照研究纳入109例在腋窝臂丛阻滞下行上肢日间手术的患者,评估术中抗痛觉过敏剂量氯胺酮(0.3 mg/kg)对反跳痛(阻滞消退后疼痛评分>7)的影响。结果显示氯胺酮未降低反跳痛发生率或强度,40.4%患者出现反跳痛;骨手术、术前严重疼痛和高疼痛灾难化是预测风险因素。
要点
- 抗痛觉过敏剂量氯胺酮不能预防外周神经阻滞后反跳痛。
- 骨手术、术前严重疼痛和高疼痛灾难化是反跳痛的预测因素。
- 反跳痛仍常见,需关注患者特异性疼痛管理。
核心结论
- 术中抗痛觉过敏剂量氯胺酮对反跳痛发生无益处。
- 中枢敏化可能不参与反跳痛,术前疼痛强度和灾难化是风险因素。
- 尽管采用适当的手术特异性术后镇痛,反跳痛仍频繁发生,未来研究应关注患者特异性疼痛管理。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照研究。
- 纳入109例在腋窝臂丛阻滞下行上肢日间手术的成人患者。
- 患者随机接受单次静脉氯胺酮0.3 mg/kg或安慰剂。
主要发现
- 109例完成研究,40.4%出现反跳痛。
- 氯胺酮给药未降低反跳痛发生率或强度。
- 有无反跳痛患者的时间总和与中枢敏化量表评分无差异。
- 预测风险因素包括骨手术(OR=5.2;CI 1.9-14.6)、术前严重疼痛(OR=4.2;CI 1.5-11.7)和高疼痛灾难化(OR=4.8;CI 1.0-22.3)。
- 第30天,反跳痛组平均每日疼痛更高,涉及神经病理性特征。
关键数值与推荐
- 反跳痛定义为阻滞消退后疼痛强度评分>7(数字评分量表,0-10)。
- 氯胺酮剂量为单次静脉0.3 mg/kg。
临床怎么用
- 抗痛觉过敏剂量氯胺酮不应常规用于预防外周神经阻滞后反跳痛。
- 对骨手术、术前严重疼痛或高疼痛灾难化患者应加强反跳痛风险评估与患者特异性镇痛管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain after resolution of peripheral nerve block, known as 'rebound pain' (RP), is a major problem in outpatient surgery. The primary objective was to evaluate the benefit of intraoperative ketamine at an anti-hyperalgesic dose on the incidence of rebound pain after upper limb surgery under axillary plexus block in ambulatory patients. The secondary objective was to better understand the rebound pain phenomenon (individual risk factors). METHODS: In this prospective, double-blind study, patients were randomised to receive either a single dose of i.v. ketamine (0.3 mg kg-1) or a placebo. Preoperative mechanical temporal summation and central sensitization inventory were applied to question underlying central sensitisation. Pain catastrophising and Douleur Neuropathique 4 questionnaires were used. Rebound pain was defined as pain intensity score >7 (numeric rating scale, 0-10) after block resolution. Postoperative pain was recorded at Days 1, 4, and 30 after discharge. RESULTS: A total of 109 subjects completed the study, and 40.4% presented with rebound pain. Ketamine administration did not reduce rebound pain incidence or intensity. Temporal summation and central sensitisation inventory scores did not differ between subjects with and without rebound pain. The predictive risk factors were bone surgery (odds ratio [OR]=5.2; confidence interval [CI], 1.9-14.6), severe preoperative pain (OR=4.2; CI, 1.5-11.7), and high pain catastrophising (OR=4.8; CI, 1.0-22.3). At Day 30, the average daily pain was higher in the rebound pain group involving neuropathic characteristics. CONCLUSION: Ketamine at an anti-hyperalgesic dose showed no benefit on rebound pain development. Although central sensitisation might not be involved, preoperative pain intensity, and catastrophising stand as risk factors. Because rebound pain remains frequent despite adequate procedure-specific postoperative analgesia, future studies should focus on patient-specific pain management.
引用
- Touil N, Pavlopoulou A, Barbier O, et al. Evaluation of intraoperative ketamine on the prevention of severe rebound pain upon cessation of peripheral nerve block: a prospective randomised, double-blind, placebo-controlled study. Br J Anaesth. 2022. PMID: 35219449. doi:10.1016/j.bja.2021.11.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。